

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 25, 2026 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted.

Adoption of the income statement and the balance sheet; allocation of result

The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with submitted accounting documents. The Annual General Meeting further resolved to allocate the company's result in accordance with the board's proposal, i.e. that the amount at the disposal of the general meeting shall be carried forward in its entirety. The resolution entails that no dividend is paid for the financial year 2025.

Discharge from liability

The Annual General Meeting resolved to discharge the board members and the managing director from liability for the financial year 2025.

Election of board members and resolution on board remuneration

The ordinary board members Robert Burns, Gillian M. Cannon, Rachel Humphrey, Jonathan Knowles, Jakob Lindberg, Anders Martin-Löf and Filippa Stenberg were re-elected as board members, all for a term of office extending until the end of the next Annual General Meeting. Mathias Uhlén had declined re-election.

Robert Burns was re-elected as chairman of the board.

It was resolved that the board's remuneration for the time until the next Annual General Meeting shall amount to SEK 500,000 to the chairperson, SEK 350,000 to the vice chairperson and SEK 250,000 to each of the other directors. In addition, it was resolved that a fee of SEK 100,000 shall be paid to the chairperson of the audit committee and a fee of SEK 25,000 to each of the members of the audit committee. It was further decided to give some additional compensation to directors residing outside of the Nordic countries in connection with physical board meetings in Sweden. No remuneration will be paid to Filippa Stenberg.

Auditor and resolution on remuneration to the auditor

The Annual General Meeting resolved to appoint the registered auditing firm Ernst & Young AB to be the auditor of the company for the period until the end of the next annual general meeting. Fees to the auditor shall be paid against approved invoice.

Adoption of new guidelines for remuneration to senior executives

The Annual General Meeting resolved to adopt new guidelines for remuneration to senior executives in accordance with the board's proposal.

Adoption of new Articles of Association

The Annual General Meeting resolved to adopt new Articles of Association where the permitted share capital and number of shares were adjusted.

Authorization for issues of shares, convertibles and warrants

It was resolved to authorize the board of directors to, on one or several occasions during the period up to the next annual general meeting, increase the company's share capital through issues of new shares, convertible instruments and/or warrants, with or without deviating from the shareholder's preferential rights, and with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody[®] molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody[®] platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Contacts (Media)

Richard Hayhurst, 59° North Communications, richard.hayhurst@59north.bio, +44 (0) 7711 8215727

Attachments

[Report from Annual General Meeting in Affibody Medical AB \(publ\)](#)